Skye Bioscience, Inc. (SKYE) Financials

SKYE Assets vs Liabilities

DateAssetsLiabilities
March 31, 2026 19.4 million 10.4 million
Dec. 31, 2025 28.3 million 8.3 million
Sept. 30, 2025 41.3 million 8.5 million
June 30, 2025 52.2 million 8.5 million

SKYE Free Cash Flow and Stock based compensation

No data available :(

SKYE Net Income

Graph available only for paid members. Upgrade to see it.
DateNet Income
March 31, 2026 -12.5 million
Dec. 31, 2025 11.1 billion
Sept. 30, 2025 -12.8 million
June 30, 2025 -17.6 million

SKYE Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 17.1 million - 60980
Dec. 31, 2025 25.7 million 83999 273646
Sept. 30, 2025 35.3 million 120207 321845
June 30, 2025 48.6 million - 367540

SKYE Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 39.7 million
Dec. 31, 2025 39.7 million
Sept. 30, 2025 39.7 million
June 30, 2025 39.7 million

SKYE Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 3 7.8 million 4.7 million -
Dec. 31, 2025 3 11.5 million 3.4 million -
Sept. 30, 2025 5 9.4 million 3.9 million -
June 30, 2025 3 14.3 million 3.9 million -

SKYE Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 172886
Dec. 31, 2025 - 180009
Sept. 30, 2025 - -
June 30, 2025 - 187066

SKYE

Price: $0.71

52 week price:
0.57
5.75

Earnings Per Share: -1.45 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 27.1 million

Links: